Agreement of CK5/6, p40, and p63 immunoreactivity in non-small cell lung cancer

被引:33
作者
Kriegsmann, Katharina [1 ]
Cremer, Martin [1 ]
Zgorzelski, Christiane [2 ]
Harms, Alexander [2 ,3 ,4 ]
Muley, Thomas [3 ,4 ,5 ]
Winter, Hauke [3 ,4 ,6 ]
Kazdal, Daniel [2 ,3 ,4 ]
Warth, Arne [7 ]
Kriegsmann, Mark [2 ]
机构
[1] Univ Hosp Heidelberg, Dept Internal Med Hematol Oncol & Rheumaol 5, Heidelberg, Germany
[2] Univ Hosp Heidelberg, Inst Pathol, Heidelberg, Germany
[3] Translat Lung Res Ctr Heidelberg, Heidelberg, Germany
[4] German Ctr Lung Res, Heidelberg, Germany
[5] Heidelberg Univ, Thoraxklin, Translat Res Unit, Heidelberg, Germany
[6] Heidelberg Univ, Thoraxklin, Dept Thorac Surg, Heidelberg, Germany
[7] UEGP, MVZ, Inst Pathol Cytopathol & Mol Pathol, Wetzlar, Limburg, Germany
关键词
NSCLC; lung cancer; CK5/6; p40; p63; CYTOKERATIN; 5/6; DIAGNOSIS; PULMONARY; DELTA-NP63; CLASSIFICATION; CARCINOMA; IMMUNOMARKERS; EXPRESSION; NAPSIN; MARKER;
D O I
10.1016/j.pathol.2018.11.009
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Histological subtyping of non-small cell lung cancer (NSCLC) is of utmost importance for therapy stratification. Common immunohistochemical markers to identify squamous lineage are CK5/6, p40, and p63. Although p40 is considered the gold standard by current guidelines, the agreement of all three markers is an important aspect for tumours more difficult to classify. A total of 1244 NSCLC including 569 squamous cell carcinomas (SqCC) and 675 adenocarcinomas were assembled on a tissue microarray and stained with CK5/6, p40, p63, TTF-1, and Napsin-A. Sensitivity and specificity for squamous lineage markers as well as agreement of CK5/6, p40 and p63 were calculated. Sensitivity of CK5/6, p40, and p63 for SqCC was 93%, 94%, and 94% and specificity was 98%, 97%, and 84%, respectively. Positivity for two of these markers was found in at least in 90% of SqCC. Highest agreement was observed for p40 and p63 (Cohen's kappa 0.80). We report a similar sensitivity of CK5/6, p40, and p63, but a decreased specificity of p63 as compared to CK5/6 and p40 for the identification of squamous lineage. Our results support the use of either CK5/6 or p40 over p63 in the routine diagnostic setting.
引用
收藏
页码:240 / 245
页数:6
相关论文
共 29 条
[1]  
Alexander M, 2017, AM J CLIN PATHOL, V147, P580, DOI [10.1093/AJCP/AQX031, 10.1093/ajcp/aqx031]
[2]   The utility of a novel triple marker (combination of TTF1, napsin A, and p40) in the subclassification of non-small cell lung cancer [J].
Ao, Ming-Hui ;
Zhang, Hui ;
Sakowski, Lynne ;
Sharma, Rajni ;
Illei, Peter B. ;
Gabrielson, Edward ;
Askin, Frederic ;
Li, Qing Kay .
HUMAN PATHOLOGY, 2014, 45 (05) :926-934
[3]   p40 (ΔNp63) is superior to p63 for the diagnosis of pulmonary squamous cell carcinoma [J].
Bishop, Justin A. ;
Teruya-Feldstein, Julie ;
Westra, William H. ;
Pelosi, Giuseppe ;
Travis, William D. ;
Rekhtman, Natasha .
MODERN PATHOLOGY, 2012, 25 (03) :405-415
[4]   Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases [J].
Chu, PGG ;
Weiss, LM .
MODERN PATHOLOGY, 2002, 15 (01) :6-10
[5]   Utilization of p40 (ΔNp63) with p63 and Cytokeratin 5/6 Immunohistochemistry in Non-Small Cell Lung Carcinoma Fine-Needle Aspiration Biopsy [J].
Collins, Brian T. ;
Wang, Jeff F. ;
Bernadt, Cory T. .
ACTA CYTOLOGICA, 2013, 57 (06) :619-624
[6]   Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer [J].
Gandhi, L. ;
Rodriguez-Abreu, D. ;
Gadgeel, S. ;
Esteban, E. ;
Felip, E. ;
De Angelis, F. ;
Domine, M. ;
Clingan, P. ;
Hochmair, M. J. ;
Powell, S. F. ;
Cheng, S. Y. -S. ;
Bischoff, H. G. ;
Peled, N. ;
Grossi, F. ;
Jennens, R. R. ;
Reck, M. ;
Hui, R. ;
Garon, E. B. ;
Boyer, M. ;
Rubio-Viqueira, B. ;
Novello, S. ;
Kurata, T. ;
Gray, J. E. ;
Vida, J. ;
Wei, Z. ;
Yang, J. ;
Raftopoulos, H. ;
Pietanza, M. C. ;
Garassino, M. C. .
NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2078-2092
[7]   Histology of non-small cell lung cancer predicts the response to stereotactic body radiotherapy [J].
Hoerner-Rieber, Juliane ;
Bernhardt, Denise ;
Dern, Julian ;
Koenig, Laila ;
Adeberg, Sebastian ;
Paul, Angela ;
Heussel, Claus Peter ;
Kappes, Jutta ;
Hoffmann, Hans ;
Herth, Felix J. P. ;
Debus, Juergen ;
Warth, Arne ;
Rieken, Stefan .
RADIOTHERAPY AND ONCOLOGY, 2017, 125 (02) :317-324
[8]   Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis [J].
Kadota, Kyuichi ;
Nitadori, Jun-ichi ;
Rekhtman, Natasha ;
Jones, David R. ;
Adusumilli, Prasad S. ;
Travis, William D. .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2015, 39 (09) :1170-1180
[9]   Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer [J].
Kerr, K. M. ;
Bubendorf, L. ;
Edelman, M. J. ;
Marchetti, A. ;
Mok, T. ;
Novello, S. ;
O'Byrne, K. ;
Stahel, R. ;
Peters, S. ;
Felip, E. .
ANNALS OF ONCOLOGY, 2014, 25 (09) :1681-1690
[10]   comprehensive immunohistochemistry algorithm for the histological subtyping of small biopsies obtained from non-small cell lung cancers [J].
Koh, Jaemoon ;
Go, Heounjeong ;
Kim, Moon-Young ;
Jeon, Yoon Kyung ;
Chung, Jin-Haeng ;
Chung, Doo Hyun .
HISTOPATHOLOGY, 2014, 65 (06) :868-878